JP2004536869A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004536869A5 JP2004536869A5 JP2003515522A JP2003515522A JP2004536869A5 JP 2004536869 A5 JP2004536869 A5 JP 2004536869A5 JP 2003515522 A JP2003515522 A JP 2003515522A JP 2003515522 A JP2003515522 A JP 2003515522A JP 2004536869 A5 JP2004536869 A5 JP 2004536869A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- alkyl
- aminocarbonyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 30
- 150000003839 salts Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 230000003287 optical effect Effects 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- -1 cyano, hydroxyl Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- QRWXQTUTFBGJHU-UHFFFAOYSA-N 2-(carbamoylamino)-5-(1h-indol-3-yl)-4-methylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CNC2=CC=CC=C12 QRWXQTUTFBGJHU-UHFFFAOYSA-N 0.000 claims 1
- DTGUWAQNQUYFQF-UHFFFAOYSA-N 2-(carbamoylamino)-5-(1h-indol-5-yl)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=C3C=CNC3=CC=2)=C1 DTGUWAQNQUYFQF-UHFFFAOYSA-N 0.000 claims 1
- SWVARBRJKGYPIV-UHFFFAOYSA-N 2-(carbamoylamino)-5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-methylthiophene-3-carboxamide Chemical compound S1C(NC(N)=O)=C(C(N)=O)C(C)=C1C1=CC=C(OCCO2)C2=C1 SWVARBRJKGYPIV-UHFFFAOYSA-N 0.000 claims 1
- HYLSCTUBXRDDOD-UHFFFAOYSA-N 2-(carbamoylamino)-5-[4-(2-morpholin-4-ylethoxy)-1-benzothiophen-2-yl]thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2SC3=CC=CC(OCCN4CCOCC4)=C3C=2)=C1 HYLSCTUBXRDDOD-UHFFFAOYSA-N 0.000 claims 1
- ACPLTAYZHQVNHA-UHFFFAOYSA-N 2-(carbamoylamino)-5-quinolin-3-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C=C3C=CC=CC3=NC=2)=C1 ACPLTAYZHQVNHA-UHFFFAOYSA-N 0.000 claims 1
- JTXJRZUQPFHBOL-UHFFFAOYSA-N 2-(carbamoylamino)-5-quinolin-8-ylthiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C3=NC=CC=C3C=CC=2)=C1 JTXJRZUQPFHBOL-UHFFFAOYSA-N 0.000 claims 1
- LQMABRNIZVPJKS-UHFFFAOYSA-N 5-(1-benzofuran-2-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2OC3=CC=CC=C3C=2)=C1 LQMABRNIZVPJKS-UHFFFAOYSA-N 0.000 claims 1
- IEMLTPOVTUCHJA-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2SC3=CC=CC=C3C=2)=C1 IEMLTPOVTUCHJA-UHFFFAOYSA-N 0.000 claims 1
- UPTJSTVOSJABLJ-UHFFFAOYSA-N 5-(1-benzothiophen-2-yl)-3-(carbamoylamino)thiophene-2-carboxamide Chemical compound S1C(C(N)=O)=C(NC(=O)N)C=C1C1=CC2=CC=CC=C2S1 UPTJSTVOSJABLJ-UHFFFAOYSA-N 0.000 claims 1
- LWXZDSSKXHVDRF-UHFFFAOYSA-N 5-(1-benzothiophen-3-yl)-2-(carbamoylamino)thiophene-3-carboxamide Chemical compound NC(=O)C1=C(NC(=O)N)SC(C=2C3=CC=CC=C3SC=2)=C1 LWXZDSSKXHVDRF-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 claims 1
- 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 150000002540 isothiocyanates Chemical class 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000000843 powder Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0102617A SE0102617D0 (sv) | 2001-07-25 | 2001-07-25 | Novel compounds |
| PCT/SE2002/001402 WO2003010163A1 (en) | 2001-07-25 | 2002-07-19 | Novel compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291103A Division JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536869A JP2004536869A (ja) | 2004-12-09 |
| JP2004536869A5 true JP2004536869A5 (https=) | 2009-09-03 |
Family
ID=20284945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003515522A Withdrawn JP2004536869A (ja) | 2001-07-25 | 2002-07-19 | 新規化合物 |
| JP2009291103A Pending JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009291103A Pending JP2010111683A (ja) | 2001-07-25 | 2009-12-22 | 新規化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7098240B2 (https=) |
| EP (1) | EP1421079B1 (https=) |
| JP (2) | JP2004536869A (https=) |
| KR (1) | KR20040018521A (https=) |
| CN (1) | CN1538968A (https=) |
| AT (1) | ATE353327T1 (https=) |
| BR (1) | BR0211472A (https=) |
| CA (1) | CA2454702A1 (https=) |
| DE (1) | DE60218048T2 (https=) |
| ES (1) | ES2280559T3 (https=) |
| IL (1) | IL160023A0 (https=) |
| MX (1) | MXPA04000755A (https=) |
| NO (1) | NO20040314L (https=) |
| NZ (1) | NZ530751A (https=) |
| SE (1) | SE0102617D0 (https=) |
| WO (1) | WO2003010163A1 (https=) |
| ZA (1) | ZA200400494B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0003154D0 (en) * | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| CN101624391A (zh) * | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| SE0102616D0 (sv) * | 2001-07-25 | 2001-07-25 | Astrazeneca Ab | Novel compounds |
| DE60229975D1 (de) * | 2001-10-04 | 2009-01-02 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| AU2003249683A1 (en) * | 2002-06-06 | 2003-12-22 | Smithkline Beecham Corporation | Nf-:b inhibitors |
| US7402608B2 (en) * | 2002-12-10 | 2008-07-22 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| SE0300092D0 (sv) | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| SE0300091D0 (sv) * | 2003-01-15 | 2003-01-15 | Astrazeneca Ab | Novel compounds |
| US7429603B2 (en) * | 2003-04-25 | 2008-09-30 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
| US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
| US7427683B2 (en) * | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
| US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
| EP1493739A1 (fr) * | 2003-07-03 | 2005-01-05 | Warner-Lambert Company LLC | Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| BRPI0418351A (pt) * | 2004-01-05 | 2007-05-08 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
| AR050253A1 (es) | 2004-06-24 | 2006-10-11 | Smithkline Beecham Corp | Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento |
| TW200626142A (en) | 2004-09-21 | 2006-08-01 | Glaxo Group Ltd | Chemical compounds |
| BRPI0610283A2 (pt) * | 2005-05-13 | 2010-10-19 | Virochem Pharma Inc | composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica |
| NZ563687A (en) | 2005-06-30 | 2011-07-29 | Smithkline Beecham Corp | 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[2-(1-methylethyl)-2,3-dihydro-1H-isoindol-5-yl]-1H-indole-7-carboxamide for inhibiting IKK2 (aka IKKbeta) |
| US8063071B2 (en) | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
| CA2670260A1 (en) | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
| CA2674865A1 (en) * | 2007-01-15 | 2008-07-24 | Santen Pharmaceutical Co., Ltd. | Indole derivative having i.kappa.b kinase .beta. inhibitory activity |
| PE20081889A1 (es) | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
| KR20130097813A (ko) | 2008-04-21 | 2013-09-03 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| US8445529B2 (en) * | 2008-07-14 | 2013-05-21 | Santen Pharmaceutical Co., Ltd. | Indole derivative having, carbamoyl group, ureido group and substituted oxy group |
| EP2319831A4 (en) * | 2008-08-25 | 2012-10-24 | Santen Pharmaceutical Co Ltd | NOVEL PYRROLE DERIVATIVE WITH A UREID GROUP, AN AMINOCARBONYL GROUP AND A BIZYCLIC GROUP EQUIPPED WITH A SUBSTITUENT AS SUBSTITUENTS |
| WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| JP7033789B2 (ja) | 2016-06-29 | 2022-03-11 | オトノミー，インク． | トリグリセリド耳用製剤とその使用 |
| CN107739370B (zh) * | 2017-10-26 | 2021-03-30 | 中国药科大学 | 吡咯酮类brd4蛋白抑制剂的制备方法以及用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1468012A (en) * | 1973-08-09 | 1977-03-23 | Beecham Group Ltd | 2-amino-3-carboxy-thiophene derivatives |
| DE3529247A1 (de) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung |
| BR9710352A (pt) | 1996-07-11 | 1999-08-17 | Pfizer | Compostos piridilpirrole |
| PT853083E (pt) | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| US6809088B2 (en) * | 1997-03-24 | 2004-10-26 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| US6037340A (en) | 1997-05-28 | 2000-03-14 | Cadus Pharmaceutical Corporation | Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| AU2713799A (en) | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
| HN2000000051A (es) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
| EP1274705A1 (en) * | 2000-03-29 | 2003-01-15 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| EP1324759A4 (en) | 2000-10-12 | 2004-05-12 | Smithkline Beecham Corp | NF - G (K) B INHIBITORS |
-
2001
- 2001-07-25 SE SE0102617A patent/SE0102617D0/xx unknown
-
2002
- 2002-07-19 EP EP02756047A patent/EP1421079B1/en not_active Expired - Lifetime
- 2002-07-19 ES ES02756047T patent/ES2280559T3/es not_active Expired - Lifetime
- 2002-07-19 CN CNA028152514A patent/CN1538968A/zh active Pending
- 2002-07-19 MX MXPA04000755A patent/MXPA04000755A/es unknown
- 2002-07-19 IL IL16002302A patent/IL160023A0/xx unknown
- 2002-07-19 WO PCT/SE2002/001402 patent/WO2003010163A1/en not_active Ceased
- 2002-07-19 CA CA002454702A patent/CA2454702A1/en not_active Abandoned
- 2002-07-19 US US10/484,645 patent/US7098240B2/en not_active Expired - Fee Related
- 2002-07-19 KR KR10-2004-7001155A patent/KR20040018521A/ko not_active Withdrawn
- 2002-07-19 AT AT02756047T patent/ATE353327T1/de not_active IP Right Cessation
- 2002-07-19 JP JP2003515522A patent/JP2004536869A/ja not_active Withdrawn
- 2002-07-19 BR BR0211472-0A patent/BR0211472A/pt not_active IP Right Cessation
- 2002-07-19 DE DE60218048T patent/DE60218048T2/de not_active Expired - Lifetime
- 2002-07-19 NZ NZ530751A patent/NZ530751A/en unknown
-
2004
- 2004-01-22 ZA ZA200400494A patent/ZA200400494B/en unknown
- 2004-01-23 NO NO20040314A patent/NO20040314L/no unknown
-
2009
- 2009-12-22 JP JP2009291103A patent/JP2010111683A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536869A5 (https=) | ||
| JP2007512299A5 (https=) | ||
| KR100900304B1 (ko) | 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체 | |
| JP2002536445A5 (https=) | ||
| JP2003503385A5 (https=) | ||
| JP2001526269A5 (https=) | ||
| JP2014526501A5 (https=) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2009520685A5 (https=) | ||
| JP2020516671A5 (https=) | ||
| JP2005538100A5 (https=) | ||
| WO2000047194A9 (en) | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | |
| ES2380704T9 (es) | Metanosulfonato de éster etílico de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1H-bencimidazol-5-carbonil)-piridin-2-il-amino]-propiónico | |
| JP2008524246A5 (https=) | ||
| JP2006528685A5 (https=) | ||
| RU2015121043A (ru) | Производные фенилэтилпиридина в качестве ингибиторов PDE-4 | |
| JP2009543843A (ja) | 直接トロンビン阻害剤に関する新規適応 | |
| JP2020512337A5 (https=) | ||
| JP2006511552A5 (https=) | ||
| CN101420950B (zh) | 杜兴肌营养不良的治疗 | |
| JP2009511513A5 (https=) | ||
| CA2819997C (en) | Preventive or therapeutic agent for pain associated with herpes zoster in acute phase | |
| JP2006510606A5 (https=) | ||
| RU2009113602A (ru) | Изосериновые производные для применения в качестве ингибиторов фактора свертывания крови ixa | |
| JP2007503432A5 (https=) |